An Open, Single-center, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of mRNA CAR-mesothelin T Cells in Patients With Advanced Refractory Solid Tumors
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Anti-mesothelin chimeric antigen receptor T cell therapy HRAIN Biotechnology/Zhejiang University (Primary) ; Cyclophosphamide; Fludarabine
- Indications Colorectal cancer; Gastric cancer; Malignant-mesothelioma; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Acronyms Amaretto
Most Recent Events
- 22 Jan 2022 Trial design presented at the 2022 Gastrointestinal Cancers Symposium
- 16 Sep 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 10 Aug 2021 to 1 Oct 2021.
- 05 Aug 2021 New trial record